✦ LIBER ✦

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

✍ Scribed by Scheerens, Heleen; Su, Zheng; Irving, Bryan; Townsend, Michael J; Zheng, Yanan; Stefanich, Eric; Chindalore, Vishala; Bingham, Clifton O; Davis, John C

Book ID: 120514840
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 260 KB
Volume: 13
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar3502

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

A multiple dose randomized double-blind

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub